Browsing by Author Tsimihodimos, V.

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Jump to: Α Β Γ Δ Ε Ζ Η Θ Ι Κ Λ Μ Ν Ξ Ο Π Ρ Σ Τ Υ Φ Χ Ψ Ω
or enter first few letters:  
View Option
Showing results 1 to 20 of 74  next >
TitleAuthor(s)Issue date
Alterations in the High Density Lipoprotein Phenotype and HDL-Associated Enzymes in Subjects with Metabolic SyndromeLagos, K. G.; Filippatos, T. D.; Tsimihodimos, V.; Gazi, I. F.; Rizos, C.; Tselepis, A. D.; Mikhailidis, D. P.; Elisaf, M. S.24-Nov-2015
Altered distribution of platelet-activating factor- acetylhydrolase activity between LDL and HDL as a function of the severity of hypercholesterolemiaTsimihodimos, V.; Karabina, S. A.; Tambaki, A. P.; Bairaktari, E.; Miltiadous, G.; Goudevenos, J. A.; Cariolou, M. A.; Chapman, M. J.; Tselepis, A. D.; Elisaf, M. S.24-Nov-2015
Altered distribution of platelet-activating factor-acetylhydrolase activity between LDL and HDL as a function of the severity of hypercholesterolemiaTsimihodimos, V.; Karabina, S. A. P.; Tambaki, A. P.; Bairaktari, E.; Miltiadous, G.; Goudevenos, J. A.; Cariolou, M. A.; Chapman, M. J.; Tselepis, A. D.; Elisaf, M.24-Nov-2015
Aminoglycoside-induced nephrotoxicity studied by proton magnetic resonance spectroscopy of urineTzovaras, V.; Tsimihodimos, V.; Kostara, C.; Mitrogianni, Z.; Elisaf, M. S.24-Nov-2015
Analysis of 6-month effect of orlistat administration, alone or in combination with fenofibrate, on triglyceride-rich lipoprotein metabolism in overweight and obese patients with metabolic syndromeFilippatos, T. D.; Tsimihodimos, V.; Kostapanos, M.; Kostara, C.; Bairaktari, E. T.; Kiortsis, D. N.; Elisaf, M. S.24-Nov-2015
Apolipoproteins C-Ii and C-Iii and Small Dense Ldl Cholesterol Levels in Non-Diabetic Obese Subjects with Metabolic SyndromeFilippatos, T.; Tsimihodimos, V.; Kostapanos, M.; Kostara, C.; Tzallas, C.; Bairaktari, E.; Tselepis, A.; Elisaf, M.24-Nov-2015
Atorvastatin preferentially reduces LDL-associated platelet-activating factor acetylhydrolase activity in dyslipidemias of type IIA and type IIBTsimihodimos, V.; Karabina, S. A. P.; Tambaki, A. P.; Bairaktari, E.; Goudevenos, J. A.; Chapman, M. J.; Elisaf, M.; Tselepis, A. D.24-Nov-2015
Atorvastatin preferentially reduces LDL-associated platelet-activating factor acetylhydrolase activity in dyslipidemias of type IIA and type IIBTsimihodimos, V.; Karabina, S. A.; Tambaki, A. P.; Bairaktari, E.; Goudevenos, J. A.; Chapman, M. J.; Elisaf, M. S.; Tselepis, A. D.24-Nov-2015
Clinical and laboratory characteristics of hypernatraemia in an internal medicine clinicLiamis, G.; Tsimihodimos, V.; Doumas, M.; Spyrou, A.; Bairaktari, E.; Elisaf, M. S.24-Nov-2015
Clinical importance and therapeutic modulation of small dense low-density lipoprotein particlesGazi, I. F.; Tsimihodimos, V.; Tselepis, A. D.; Elisaf, M. S.; Mikhailidis, D. P.24-Nov-2015
Cola-induced hypokalaemia: pathophysiological mechanisms and clinical implicationsTsimihodimos, V.; Kakaidi, V.; Elisaf, M. S.24-Nov-2015
Combinations of ezetimibe with nonstatin drug regimens affecting lipid metabolismAgouridis, A. P.; Filippatos, T. D.; Tsimihodimos, V.; Elisaf, M. S.24-Nov-2015
Combined treatment with fibrates and small doses of atorvastatin in patients with mixed hyperlipidemiaLiamis, G.; Kakafika, A.; Bairaktari, E.; Miltiadous, G.; Tsimihodimos, V.; Goudevenos, J.; Achimastos, A.; Elisaf, M. S.24-Nov-2015
Comparison of the efficacy of atorvastatin and micronised fenofibrate in the treatment of mixed hyperlipidemiaMiltiadous, G.; Bairaktari, E.; Tzallas, C.; Tsimihodimos, V.; Liberopoulos, E.; Millionis, H.; Rizos, E.; Elisaf, M. S.24-Nov-2015
Concentration and relative distribution of low-density lipoprotein subfractions in patients with metabolic syndrome defined according to the National Cholesterol Education Program criteriaGazi, I.; Tsimihodimos, V.; Filippatos, T.; Bairaktari, E.; Tselepis, A. D.; Elisaf, M.24-Nov-2015
Disturbances of phosphate metabolism: another feature of metabolic syndromeKalaitzidis, R.; Tsimihodimos, V.; Bairaktari, E.; Siamopoulos, K. C.; Elisaf, M. S.24-Nov-2015
Does micronized fenofibrate affect PAF-Acetylhydrolase activity?Elisaf, M. E.; Tsimihodimos, V.; Bairaktari, E.; Tambaki, A.; Tselepis, A.; Papathanasiou, A.; Goudevenos, I.24-Nov-2015
Dyslipidemia associated with chronic kidney diseaseTsimihodimos, V.; Mitrogianni, Z.; Elisaf, M. S.24-Nov-2015
Dyslipidemia in chronic kidney disease: an approach to pathogenesis and treatmentTsimihodimos, V.; Dounousi, E.; Siamopoulos, K. C.24-Nov-2015
Editorial: secondary dyslipidemiasElisaf, M. S.; Tsimihodimos, V.24-Nov-2015